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THE IMPACT OF SIMVASTATIN LAUNCHING ON EXISTING
LIPITOR PATIENTS IN A MANAGED CARE SETTING
Jiang JZ, Fuldeore M, Huang Z, Meller CP, Khandelwal NG, Lee KY
Walgreens Health Services, Deerﬁeld, IL, USA
OBJECTIVES: Lipitor is one of the most commonly prescribed
statins in the United States. The approval of generic Zocor (sim-
vastatin) by the Food and Drug Administration on 06/23/2006,
brought about the question of how this product may inﬂuence
the switching pattern on existing Lipitor patients. METHODS:
A large employer based pharmacy claim database was used in this
study from 01/01/2005 to 12/31/2006. The impact of simvastatin
on existing Lipitor patients was evaluated as follows. The rate
ratio was computed in order to assess Lipitor switching. Those
patients who were exclusively on Lipitor from 01/01/2005 to
06/30/2005 were included in control group and those exclusively
taking Lipitor between 01/01/2006 and 06/30/2006 were selected
in study group. Patients in both groups were followed-up for an
additional six months and their respective switching rates were
computed and compared using Chi-square analysis. RESULTS:
A total of 24,137 control group patients and 23,869 study group
patients were identiﬁed from administrative pharmacy claims
database. About 865(3.6%) patients in the study group and
632(2.6%) patients in the control groups switched to alternative
statins after their respective follow-up periods. Study group
patients were 1.4 times more likely to switch to alternative statins
than control group patients (P < 0.001; 95% CI, 1.3–1.6). Specif-
ically, the study group patients were 5.1 times (P < 0.001; 95%
CI, 4.0–6.6) more likely to switch to simvastatin, and 2.0 times
(P < 0.001; 95% CI, 1.5–2.6) more likely to switch to Crestor. In
both groups, study group patients were 2.0 times (P < 0.001; 95%
CI, 1.5–2.8) less likely to switch to lovastatin and 1.3 times (P <
0.001; 95% CI, 1.1–1.6) less likely to switch to vytorin. CON-
CLUSION: The results suggest that majority of the study group
patients’ tend to switch to simvastatin and their switching behav-
ior could have resulted due to the fact that simvastatin became
available as a generic version.
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PROFILES OF INITIAL DRUG THERAPIES AMONG NEWLY
DIAGNOSED HYPERTENSIVE PATIENTS WITH NO
COMPELLING INDICATIONS
Ganguli A, Dr. Hong SH
University of Tennessee, Memphis,TN, USA
OBJECTIVES: Over a billion people globally and nearly 50
million people in US population suffer from hypertension. Evi-
dences suggest that the initial drug of choice in clinical practice
is different from JNC (Joint National Committee) guidelines.
Timely treatment of newly diagnosed hypertensive patients is a
key step to control the disease and hence the initial choice of
drug becomes a crucial decision in the disease management. The
study aims to describe the patterns of drug therapy initiation
among newly diagnosed hypertensive patients and to com-
pare the patterns between different hypertension severities.
METHODS: The study is a retrospective analysis of newly diag-
nosed hypertension patients with SBP (systolic blood pressure)
°Y´140 mmHg, or DBP (diastolic blood pressure) °Y´90 mmHg,
with no recent history of hypertension and no compelling co-
morbidities. Newly diagnosed hypertensive patients were identi-
ﬁed with high blood pressure in medical records along with no
existence of hypertension drug therapy in the one year prior to
the initial drug therapy. Drugs in pharmacy claims were identi-
ﬁed using a proprietary drug database. RESULTS: A total of 169
patients were identiﬁed as study sample comprising of 88 males
and 81 females. The percent who had stage 1 hypertension was
37.47% (64 patients). Diuretics was most frequent initial drug
of choice in patients with stage 1 hypertension (45.32%, 95%
CI: 37.81–52.82%) and in stage 2 hypertension (46.67%, 95%
CI: 39.14–54.19%). Monotherapy was preferred over combina-
tion therapy in stage 1 hypertension patients (87.5%, 95% CI:
82.51–92.48%). Monotherapy was still preferred over combi-
nation therapy in stage 2 (73.34%, 95% CI: 71.23–80.00%)
hypertension. CONCLUSION: Differences still exist in clinical
practice and JNC guidelines with regards to initial drug of choice
in newly diagnosed hypertensive patients with no compelling
indications. More emphasis.
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PROJECTED COST SAVINGS COMPARISON TO MANAGED
CARE ORGANIZATIONS FOR THE YEAR FOLLOWING
GENERIC SIMVASTATIN AND PRAVASTATIN AVAILABILITY IN
THE US
Gandhi PK1, Spooner JJ2, Groesbeck JM2, Segal R1
1University of Florida-Gainesville, Gainesville, FL, USA, 2Advanced
Concepts Institute, Philadelphia, PA, USA
OBJECTIVES: To estimate drug acquisition cost savings com-
parisons for managed care organizations (MCOs) with avail-
ability of generic simvastatin and pravastatin in the US.
METHODS: A deterministic study ascertained potential cost
savings for MCOs with availability of generic simvastatin and
pravastatin. The study focused on patients requiring less 
substantial cholesterol reduction (<30% LDL-C reduction).
National statin prescription sales (November 2004–October
2005) were obtained; dose interchange table was developed iden-
tifying statin switches providing LDL-C lowering effect within
10% of the entry drug. The study assumed all patients requiring
an LDL reduction of <30% would switch from other equivalent
statin doses to simvastatin 5 mg or pravastatin 10 mg daily. Two
assumptions with four cost scenarios for generic simvastatin and
pravastatin prices were tested: 15% rebate for branded statins,
50% discount rate for generics, and $5 generic and $15 brand
co-payments (assumption 1) or 15% rebate for branded statins,
60% discount rate for generics, and $10 generic and $20 brand
co-payments (assumption 2). Sensitivity analyses varying dis-
count rates and co-payments for generic products were per-
formed. RESULTS: Total baseline costs to MCOs for branded
statins were $0.88B (assumption 1) and $0.80B (assumption 2)
for patients eligible to switch to generic simvastatin and $0.78B
and $0.69B, respectively, for patients eligible to switch to generic
pravastatin. Switching patients to generic simvastatin lowered
total costs to $0.53B and $0.32B, providing cost savings for
TPPs of $0.36B and $0.48B. Switching patients to generic
pravastatin changed total costs to $0.81B and $0.55B, generat-
ing cost expenditures of $0.03B and cost savings of $0.15B,
respectively. CONCLUSIONS: With varying assumptions in the
study, switching patients requiring less substantial cholesterol
reduction to generic simvastatin generated substantial cost
savings compared to generic pravastatin. Extended studies focus-
ing on economic impacts on MCOs are encouraged to evaluate
cost savings following availability of other generic and combi-
nation statin drugs.
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BLOOD PRESSURE CONTROL THROUGH PATIENT AND
PHYSICIAN EDUCATION PROGRAMS
Shaya FT1, Gu A1, Saunders E2
1University of Maryland School of Pharmacy, Baltimore, MD, USA,
2University of Maryland School of Medicine, Baltimore, MD, USA
OBJECTIVES: The purpose of this study is to assess the impact
of patient and physician education on blood pressure control in
